Vibegron Patent Expiration
Vibegron is Used for treating overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. It was first introduced by Urovant Sciences Gmbh
Vibegron Patents
Given below is the list of patents protecting Vibegron, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Gemtesa | US12102638 | Use of vibegron to treat overactive bladder | Mar 22, 2040 | Urovant |
| Gemtesa | US12180219 | Process for preparing beta 3 agonists and intermediates | Mar 12, 2034 | Urovant |
| Gemtesa | US8247415 | Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists | Dec 01, 2030 | Urovant |
| Gemtesa | US8653260 | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists | Apr 02, 2029 | Urovant |
Vibegron's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Vibegron:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry. Vibegron has 3 clinical trials that have been verified in 2024.